| Literature DB >> 22531277 |
Abstract
Inhibitors of the mammalian target of rapamycin (mTOR) are administered as immunosuppressant as well as antineoplastic agents. Because of the narrow therapeutic index of mTOR inhibitors, drug monitoring is required, and this is usually done by measuring blood drug levels. Increasing knowledge of the signaling pathways of the mTOR protein kinase provides an opportunity for pharmacodynamic drug monitoring. With the different laboratory methods it is becoming possible to measure new biomarkers to control the influence of mTOR activity. One of these biomarkers is phospho-S6 kinase, with its isoform p70S6K.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22531277 DOI: 10.1016/j.cca.2012.03.023
Source DB: PubMed Journal: Clin Chim Acta ISSN: 0009-8981 Impact factor: 3.786